ClinicalTrials.gg
TerminatedNCT00508274Updated Sep 21, 2021Results posted

Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China

A Phase 3 interventional study of lapatinib and capecitabine in Neoplasms, Breast, sponsored by Novartis Pharmaceuticals. Terminated at 11 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
44th of 114
52 · median 35
Started
2007
with 15 others
Phase 3
18 of 114
none open now
Registered
45th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 44th largest by enrollment, is one of 16 that started in 2007, is one of 18 in phase 3, and was the 45th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

Local study in China and Hong Kong to evaluate safety and efficacy in lapatinib + capecitabine in women with Human epidermal growth factor receptor 2 (HER2) positive advanced or metastatic breast cancer.

Read the detailed description

The Primary objective of the study was to evaluate the overall clinical benefit response (CBR) rate.

This was a single arm, open-label, multi-center study of lapatinib plus capecitabine in women from mainland China and Hong Kong who had advanced or metastatic breast cancer that progressed on prior chemotherapies with or without trastuzumab.

Participants received study treatment until disease progression, unacceptable toxicity, or withdrawal for any other reasons.

03

Conditions studied

  • Neoplasms, Breast

Browse trials for

Keywords

  • Advanced Metastatic Breast Cancer
  • HER2 positive
  • HER2+
  • breast cancer
  • lapatinib
  • TYVERB
  • TYKERB
  • Capecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ;
  • Female ≥18 years;
  • Pathology that has confirmed invasive breast cancer with stage IIIb/c or stage IV disease;

    • If recurrent disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology or histology.
  • Documented overexpression of Her2 (ErbB2) of IHC 3+ or FISH positive, in primary or tumor tissue is required for enrollment into the study; by local testing or central laboratory testing determined by country of residence. NB. Approximately, 51 subjects will be enrolled in a single stage design to test for efficacy in women from China and Hong Kong. Due to the fact that trastuzumab is not commonly prescribed in China and Hong Kong, the current study allows up to 40% of subjects who are trastuzumab naïve to be enrolled.
  • Prior therapies must include at minimum a taxane and/or anthracycline and may include trastuzumab if available; other prior regimens are not limited except capecitabine and Erbb2 inhibitors other than trastuzumab. Chemo regimen requirements are as follows:

    • Taxane containing regimen for at least 4 cycles or \<4 cycles provided disease progression or treatment limiting toxicity occurred while on taxane
    • Anthracycline containing regimen for at least 4 cycles or \<4 cycles provided disease progression or treatment limiting toxicity occurred while on anthracycline
    • Taxanes and Anthracyclines may have been administered concurrently or separately
    • Prior treatment may have contained trastuzumab alone or in combination with other chemotherapy in the adjuvant, locally advanced or metastatic setting and patient must have failed the treatment
    • Prior treatment with capecitabine is not permitted unless 6 months have elapsed since the last dose of capecitabine and the subject is free of any capecitabine related toxicity
    • Prior therapy with an ErbB1 and/or ErbB2 inhibitor, other than trastuzumab is not permitted
    • Other prior chemo-regimens not listed above are unlimited.
  • For those subjects whose disease is ER+ and/or PR+ one of following criteria should be met.

    • Subjects who received hormonal therapy and are no longer benefiting from this therapy and the hormonal treatment must have been stopped before the first dose of treatment
    • Subjects with visceral disease that requires chemotherapy (eg., subjects with liver or lung metastases)
    • Rapidly progressing or life threatening disease, as determined by the investigator
  • Subjects with stable (asymptomatic and off systemic and anticonvulsants for at least 3 months) are eligible
  • (s) according to (Response Evaluation Criteria in Solid Tumors);
  • Radiotherapy as palliative treatment for painful metastatic disease is permitted but must have been stopped within 2 weeks prior to initiation of any investigational treatment. All subjects must have recovered from all radiotherapy related toxicities prior to initiation of any investigational treatment. The site of radiotherapy must not be used as a site of measurable disease;
  • Cardiac within institutional range of normal as measured by echocardiogram. MUGA scans will be accepted in cases where an echocardiogram cannot be performed or is inconclusive;
  • Performance Status of 0 to 1;
  • of ≥ 12 weeks;
  • Able to swallow and retain oral medication;
  • Women with potential to have children must be willing to practice acceptable methods of during the study;
  • Willing to complete all screening assessments as outlined in the protocol;
  • Adequate organ function as defined by the Table of Baseline Laboratory Values

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females at anytime during the study
  • Subjects with only non-measurable sites of disease per , (e.g. bone metastases, pleural effusion, or ascites, etc.);
  • Planned concurrent anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy) while taking treatment;
  • Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;
  • History of other . However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma, are eligible;
  • Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety;
  • Uncontrolled infection;
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of ;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    lapatinib in combination with capecitabine

    daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)

    Drug: lapatinib · Drug: capecitabine

Interventions

  • Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets taken orally.

    Also known as: LAP016, GW572016

  • Capecitabine is supplied as a biconvex, oblong, light peach and peach colored, film-coated tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A "partial response" requires a decrease of 30% or more, "complete response" requires all target lesions disappear, "Progression" requires an increase of at least 20%, and "Stable disease" falls in between these two. All responses have a repeat assessment to confirm the response.

    Time frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first.

    Time frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.

  2. Six Months Progression-Free Survival

    Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment.

    Time frame: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.

  3. Time to Response (TTR)

    Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response.

    Time frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months

  4. Duration of Response (DOR)

    Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response.

    Time frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.

  5. Number of Participants With Central Nervous System (CNS) as First Site of Relapse

    Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment.

    Time frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months

07

Results

Posted Sep 3, 2009
Limitations and caveats
Data collection post 1-Jul-2019 was not reportable due to local regulations in China.

Participant flow

Participant flow — Overall Study
MilestoneLapatinib + Capecitabine
Started52
Completed2
Not completed50
Withdrew: Adverse event5
Withdrew: Death7
Withdrew: Disease progression32
Withdrew: Withdrawal by subject1
Withdrew: Subject received new anti-cancer chemotherapy/traditional chinese medicine2
Withdrew: Missing3

Outcome measures

PrimaryClinical Benefit Rate (CBR)

CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A "partial response" requires a decrease of 30% or more, "complete response" requires all target lesions disappear, "Progression" requires an increase of at least 20%, and "Stable disease" falls in between these two. All responses have a repeat assessment to confirm the response.

Time frame:
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR)
Percentage of participantsLapatinib + Capecitabine
Clinical Benefit Rate (CBR)57.7 (43.2 to 71.3)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first.

Time frame:
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsLapatinib + Capecitabine
Progression-Free Survival (PFS)6.34 (0.03 to 90.38)
SecondarySix Months Progression-Free Survival

Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment.

Time frame:
at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.
Reported as:
Number · Percentage of participants
Six Months Progression-Free Survival
Percentage of participantsLapatinib + Capecitabine
Six Months Progression-Free Survival53.55 (38.77 to 66.25)
SecondaryTime to Response (TTR)

Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response.

Time frame:
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months
Reported as:
Median · Months
Time to Response (TTR)
MonthsLapatinib + Capecitabine
Time to Response (TTR)4.07 (2.73 to 14.78)
SecondaryDuration of Response (DOR)

Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response.

Time frame:
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.
Reported as:
Median · Months
Duration of Response (DOR)
MonthsLapatinib + Capecitabine
Duration of Response (DOR)8.18 (2.69 to 88.80)
SecondaryNumber of Participants With Central Nervous System (CNS) as First Site of Relapse

Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment.

Time frame:
Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months
Reported as:
Number · participants
Number of Participants With Central Nervous System (CNS) as First Site of Relapse
participantsLapatinib + Capecitabine
Participants with any site of relapse17
Participants with CNS disease as first site of relapse2
Post-hocAll Collected Deaths

On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV).

Time frame:
up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsLapatinib + Capecitabine
Total Deaths11
On-treatment Deaths2

Adverse events

Collected over On treatment deaths were collected from FPFT up to 30 days after study drug discontinuation, for a maximum duration of 4276 days for Lapatinib, including the 30 days safety follow- up (treatment duration ranged from 13 to 4246 days) and 3384 days for Capecitabine, including the 30 days safety follow up (treatment duration ranged from 8 to 3354 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lapatinib + Capecitabine2/52 (3.8%)4/52 (7.7%)49/52 (94.2%)
Most frequent serious events
Most frequent serious events
EventLapatinib + Capecitabine
LeukopeniaBlood and lymphatic system disorders1/52
NeutropeniaBlood and lymphatic system disorders1/52
ThrombocytopeniaBlood and lymphatic system disorders1/52
Cervix CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/52
Vaginal Cancer Stage 0Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/52
HaemoptysisRespiratory, thoracic and mediastinal disorders1/52
Most frequent other events
Showing 10 of 25
Most frequent other events
EventLapatinib + Capecitabine
Palmar-Plantar Erythrodysaesthesia SyndromeSkin and subcutaneous tissue disorders32/52
DiarrhoeaGastrointestinal disorders26/52
RashSkin and subcutaneous tissue disorders26/52
HyperbilirubinaemiaHepatobiliary disorders20/52
FatigueGeneral disorders13/52
NauseaGastrointestinal disorders9/52
NeutropeniaBlood and lymphatic system disorders7/52
Mouth UlcerationGastrointestinal disorders6/52
StomatitisGastrointestinal disorders5/52
Blood Bilirubin IncreasedInvestigations5/52

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lapatinib + Capecitabine
Mean48.8 ± 10.61
Sex: Female, Male
Sex: Female, Male(Participants)Lapatinib + Capecitabine
Female52
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lapatinib + Capecitabine
Chinese52
08

Study locations

11 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 510060, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510515, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210009, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310006, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310022, China
  • Novartis Investigative Site
    Beijing, 100021, China
  • Novartis Investigative Site
    Beijing, 100071, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Shatin, Hong Kong
09

References and documents

Publications

  • Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, Preston A, Martin AM, Chi HD, Wang L. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Cancer. 2011 May;30(5):327-35. doi: 10.5732/cjc.010.10507. PubMed 21527065 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2007 to primary completion in Dec 2015, 100 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2007
First posted
Jul 27, 2007
StartActual
Jul 18, 2007
Primary completionActual
Dec 2, 2015
CompletionActual
Jul 1, 2020
Results first posted
Sep 3, 2009
Last update
Sep 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00508274
Responsible party
Sponsor
First posted
Jul 27, 2007
Start date
Jul 18, 2007
Primary completion
Dec 2, 2015
Completion
Jul 1, 2020
Results posted
Sep 3, 2009
Last update
Sep 21, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Capecitabine

Start the discussion